MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports

Rhea-AI Summary

MIMEDX Group, Inc. (Nasdaq: MDXG) announced the publication of a peer-reviewed study in Nature – Scientific Reports, focusing on how placental-based allografts may modulate scarring and fibrosis in surgical procedures. The study, titled "Human amniotic membrane modulates collagen production and deposition in vitro," is MIMEDX's first publication in this prestigious journal.

The research evaluated two configurations of PURION processed placental-based allografts: dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM). Both demonstrated modulation of collagen production, deposition, and maturation, supporting the hypothesis that amniotic membranes may interrupt pathological fibrosis and restore tissue homeostasis.

This study adds to MIMEDX's growing body of evidence and expands the understanding of their allografts' regulatory capabilities in the fibrotic process, potentially leading to improved patient outcomes in procedures where pathological fibrosis results in detrimental scarring and dysfunctional tissue.

Positive

• Publication in Nature – Scientific Reports, the 5th most-cited journal globally
• Study demonstrates potential mechanism for MIMEDX's allografts to modulate scarring and fibrosis
• Expands understanding of DHACM and LHACM allografts' regulatory capabilities
• Supports potential applications for amniotic membranes in improving patient outcomes
• Reinforces MIMEDX's commitment to innovation based on science and clinical evidence

Negative

• None.

Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process

Marks MIMEDX’s first publication in the 5^th most-cited journal in the world

MARIETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of a peer reviewed study characterizing a potential mechanism by which placental-based allografts modulate the occurrence of scarring and fibrosis in surgical procedures. The article, “Human amniotic membrane modulates collagen production and deposition in vitro” represents the Company’s first publication in Nature and can be accessed online here.

“We are pleased to have this study published in Nature – Scientific Reports, a leading, peer-reviewed journal with a reputation for publishing best-in-class scientific literature,” stated Michelle Massee, MIMEDX Vice President of R&D. “In addition to developing market-leading products, our aim is to continue to generate the industry’s most comprehensive library of clinical and scientific publications in support of our products’ use and efficacy. Through our research we hope to identify additional potential applications for amniotic membranes to improve patient outcomes. With the industry as a whole placing greater importance on generating robust clinical data in the field of skin substitutes, we believe that the addition of this study reaffirms our commitment to lead this field with innovation based on science and clinical evidence.”

The study evaluated two configurations of PURION processed placental-based allografts for their ability to regulate fibrotic processes as modeled in a physiologically relevant in vitro system. Both dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) demonstrated modulation of collagen production, deposition, and maturation in support of the hypothesis that amniotic membranes may function to interrupt pathological fibrosis and restore tissue homeostasis. The relevance of this study is significant to procedures where pathological fibrosis results in detrimental scarring and dysfunctional tissue. These findings expound on the multi-modal mechanism by which amniotic tissue supports the resolution of acute and chronic wounds.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What is the significance of MIMEDX's study published in Nature – Scientific Reports?

The study, published in a prestigious journal, demonstrates how MIMEDX's placental-based allografts may modulate scarring and fibrosis in surgical procedures, potentially leading to improved patient outcomes and expanding the understanding of their products' capabilities.

What types of MIMEDX allografts were evaluated in the study?

The study evaluated two configurations of PURION processed placental-based allografts: dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM).

How might MIMEDX's (MDXG) allografts benefit surgical procedures?

The study suggests that MIMEDX's allografts may function to interrupt pathological fibrosis and restore tissue homeostasis, potentially reducing detrimental scarring and improving functional outcomes in surgical procedures.

What is the title of MIMEDX's study published in Nature – Scientific Reports?

The study is titled "Human amniotic membrane modulates collagen production and deposition in vitro."